Antibodies News and Research

RSS

Teclistamab delivers deeper responses in relapsed myeloma patients

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

29 May 2026

Survey reveals critical knowledge gaps in maternal health recommendations

Most Americans know that how well a mother takes care of herself before and during pregnancy affects the health of a baby, but many people remain unclear about some specific maternal health recommendations, including when to start avoiding alcohol, according to a new nationally representative survey from the Annenberg Public Policy Center (APPC) of the University of Pennsylvania.

29 May 2026

WHO prioritizes candidate vaccines and therapeutics for Bundibugyo virus

In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups.

29 May 2026

Experimental vaccine triggers broadly neutralizing HIV antibodies in macaques

For years, researchers have been hoping for vaccines that protect people against not just one strain of HIV, but every strain of the quickly mutating virus.

28 May 2026

Mount Sinai study links long COVID symptoms to autoimmunity

A Mount Sinai-led research team has demonstrated that autoimmunity, where the body's immune system attacks its own tissues, is responsible for the often-debilitating and confounding symptoms of long COVID in a subset of people.

28 May 2026

Scientists develop safer CRISPR technique using gentler DNA nicking approach

Researchers at Cornell University have developed a safer and more precise way to study how genes function in living tissues by refining a recently developed CRISPR-based genetic technique in fruit flies, enabling researchers to better study how genes contribute to development and disease.

27 May 2026

Scientists reveal why common pancreatic precancer lesions rarely turn deadly

Spatial and single-cell analyses of human donor pancreata showed that PanIN epithelial cells gradually acquire cancer-like molecular features, while their surrounding stromal and immune environment remains closer to normal pancreatic tissue. The findings suggest that delayed or incomplete microenvironmental reprogramming may help explain why most PanIN lesions remain indolent rather than progressing to pancreatic cancer.

24 May 2026

New computational pipeline improves effectiveness of pan-Ebola neutralizing antibodies

A team led by Professor Wei Yang at the National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, has developed a computational-experimental pipeline that synergistically optimizes antibody framework regions (FR) and complementarity-determining regions (CDR).

24 May 2026

Shared humor and play strengthen children’s brains and emotional wellbeing

Making children laugh can build deep emotional connections and soothe their nervous systems, making them more resilient and open to new ideas, a leading child development expert tells us.

24 May 2026

Boston Children's scientists create new booster-free mRNA vaccine strategy

In a new study published in Nature Immunology, researchers at Boston Children's Hospital demonstrated that pairing the original COVID-19 mRNA vaccine with an immune system enhancer, known as an adjuvant, extended the duration of the vaccine's protection in mice from a few months up to two years.

22 May 2026

Study finds widespread hantavirus exposure among Pacific Northwest rodent populations

The Sin Nombre virus – a hantavirus that can cause a deadly respiratory disease in humans – may be more widespread among rodent populations in parts of the Pacific Northwest than previously recognized.

21 May 2026

AI-created miniproteins show promise for targeting hard-to-treat diseases

G protein-coupled receptors, or GPCRs, sit in the plasma membrane, the boundary that defines the inside and outside of a living cell. They communicate with nearly every physiological process in our bodies - from the ability to see and smell, to sensing of adrenaline, insulin, nutrients and medicines.

21 May 2026

New immuno-infrared sensor aids in early diagnosis of Alzheimer’s and Parkinson’s disease

An early start to treatment is crucial to successful therapy. A new sensor is helping with early detection.

21 May 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Rerouting dead tumor debris enhances cancer immunotherapy outcomes

As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual cancer cells die, exposing their internal scaffolds.

20 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

Sino Biological launches XPressMAX™ Cell-Free Protein Synthesis Kit, accelerating AI-powered high-throughput antibody drug discovery

Sino Biological, Inc., a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02) , a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery.

From Sino Biological Inc. 20 May 2026

Ensitrelvir cuts household COVID-19 risk when given after exposure

Ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor, reduced symptomatic RT-PCR-confirmed COVID-19 among household contacts when given within 72 hours after symptom onset in the infected index patient. In the phase 3 SCORPIO-PEP trial, COVID-19 occurred in 2.9% of ensitrelvir recipients versus 9.0% of placebo recipients, with similar overall adverse-event rates.

20 May 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

Identifying the methodology gap that prevents treatment of infection-triggered chronic diseases

Thousands of Americans develop chronic persistent symptoms-such as fatigue, cognitive difficulties ("brain fog"), and other debilitating issues-each year following acute infections from Lyme disease, COVID-19, and other pathogens. Efforts to identify causes and produce treatments have failed. However, 16 leading researchers think they know part of the problem: study design.

14 May 2026